Press releases
April 9, 2024
2023 annual results, growth in Core Business and strategic deployment
January 9, 2024
Capital reduction through cancellation of treasury shares
November 7, 2023
Catherine Courboillet to join the Board as an Independant Member
October 11, 2023
H1 2023 Results: Solid performance of Core Business and acceleration of strategic deployment
July 24, 2023
Acceleration of strategic deployment in the first half of 2023
July 11, 2023
Capital reduction through cancellation of treasury shares
June 16, 2023
All resolutions approved at the 2023 Annual General Meeting - The Board of Directors appoints a new governance
April 5, 2023
2022 annual results : very strong performance and strengthening of the Core Business
February 14, 2023
Wietse Mulder, CEO of GenDx, holds a 2% stake in Eurobio Scientific
February 8, 2023
Eurobio Scientific formalises the appointment of Anne-Sophie Herelle as Group CFO
November 22, 2022
Exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer
October 11, 2022
H1 2022 Results: continued growth of non-COVID activity
October 3, 2022
Eurobio Scientific finalizes the acquisition of GenDx, international HLA diagnostics specialist
August 17, 2022
Eurobio Scientific signs an agreement to acquire GenDx, international HLA diagnostics specialist
July 25, 2022
First half turnover of €83.6 million maintained at a high level
June 20, 2022
Launch of 2 new proprietary tests : new variants of SARS-CoV-2, and Monkeypox
June 13, 2022
Eurobio Scientific expands into Benelux by acquiring the diagnostic company Biomedical Diagnostics NV
May 18, 2022
Closing of the Strategic Partnership with NEXTSTAGE AM
April 26, 2022
Eurobio Scientific partners with Dr. Nino Guy Cassuto for the development of a new PCR test for male fertility
April 14, 2022
CE mark for Eurobio Scientific’s new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2
March 10, 2022
New priority test for the detection of Omicron BA.x, BA.2 and Delta of SARS-CoV-2
January 24, 2022
2021 TURNOVER : Exceptional level of €184.1million
January 11, 2022
Eurobio Scientific launches the exclusive distribution of the first saliva self-test for HIV testing in France
December 13, 2021
Eurobio Scientific obtains CE marking for its proprietary test for Covid-19 screening and detection of the Omicron and Delta variants
November 30, 2021
Omicron variant : Eurobio Scientific launches the first PCR test allowing simultaneous SARS-CoV-2 virus screening and detection of the Delta and Omicron variants in a single reaction
November 23, 2021
Eurobio Scientific makes a minority investment in Usense
October 12, 2021
2021 Half-year earnings : EBITDA up +110% to €42.5m
October 6, 2021
Eurobio Scientific receives a $430,000 milestone payment from Allergan
July 26, 2021
First half turnover reaches €95.7 million, a 54% increase
May 26, 2021
Eurobio Scientific launches a new proprietary test for simultaneous detection of the SARS-CoV-2 virus and characterization of its new mutations
March 9, 2021
EUROBIO Scientific extends its family of proprietary PCR tests to allow the identification of SARS-CoV-2 variants
January 25, 2021
Exceptional 2020 turnover of € 189 million (+220%)
January 18, 2021
Eurobio Scientific expands its range of COVID-19 tests with an antigenic rapid test
September 22, 2020
Eurobio Scientific launches a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen
September 15, 2020
Eurobio Scientific announces the CE marking of its COVID EBX FluCoSyn™ PCR test
July 21, 2020
Very strong growth of business during the first half of 2020
July 15, 2020
Eurobio Scientific expands into Switzerland, Germany, Austria and Benelux with the acquisition of TECOmedical AG
May 13, 2020
Eurobio Scientific and the Hospices Civils de Lyon join forces to develop a bank of anti-SARS CoV-2 antibodies
May 11, 2020
Eurobio Scientific's proprietary PCR test confirmed as part of the fight against COVID-19
May 5, 2020
Eurobio Scientific and NG Biotech enter into a marketing agreement for COVID-19 serology rapid tests
March 31, 2020
Eurobio Scientific launches MagLumi COVID-19 automated test from its partner SNIBE for COVID-19 serology
March 25, 2020
Eurobio Scientific gets CE marking for its proprietary COVID-19 test
January 27, 2020
Eurobio Scientific anounced full-year revenues up 17% to €59.1M
November 4, 2019
Eurobio Scientific enters into a strategic agreement for the development of proprietary products in molecular biology
October 15, 2019
Strong Earnings Growth for the First Half of 2019
October 1, 2019
Eurobio Scientific joins the Enternext PEA PME 150 index
June 12, 2019
Eurobio Scientific and Vivo Medical Group enter into exclusive negociations for the acquisition of two companies in the United Kingdom
January 29, 2019
Eurobio Scientific reaches the €50M sales mark in 2018
January 8, 2019
Eurobio Scientific announces its financial communication calendar for 2019
October 31, 2018
Lending of bond funds of €2.5M with Vatel Direct (French version)
October 17, 2018
Eurobio Scientific and BIOGROUP-LCD enter into an agreement for the supply and maintenance of Multiplex Molecular Biology automated platforms
July 23, 2018
Consolidated turnover for the fist semester of 2018 increases by 29%
